不同剂量甲泼尼龙对重症社区获得性肺炎患者临床结局的影响:一项随机对照试验的研究方案
本研究为前瞻性、随机、双盲、平行组、安慰剂对照试验,将重症社区获得性肺炎(SCAP)患者按1:1:1:1随机分为四组,分别接受标准ICU治疗加安慰剂或甲泼尼龙40mg、80mg、120mg每日一次共5天,主要结局为随机化后第5天PaO2/FiO2比值,旨在评估不同剂量甲泼尼龙的疗效与安全性。
要点
- SCAP患者随机接受甲泼尼龙40mg、80mg、120mg或安慰剂每日一次共5天。
- 主要结局为随机化后第5天PaO2/FiO2比值。
- 次要结局包括28天死亡率、无机械通气天数、机械通气时长等。
核心结论
- 研究结果可能找到糖皮质激素辅助治疗SCAP的最佳剂量,并为临床医生治疗SCAP提供循证依据。
- 由于COVID-19也属于社区获得性肺炎,本研究结果或许有助于确定COVID-19治疗中甲泼尼龙的适当剂量。
研究设计与样本
- 前瞻性、随机、双盲、平行组、安慰剂对照试验。
- 确诊SCAP的患者按1:1:1:1比例随机分为四组。
- 第1组(对照组):标准ICU治疗+100ml生理盐水每日一次共5天。
- 第2组:标准ICU治疗+甲泼尼龙40mg(溶于生理盐水,终体积100ml)每日一次共5天。
- 第3组:标准ICU治疗+甲泼尼龙80mg(溶于生理盐水,终体积100ml)每日一次共5天;第4组:标准ICU治疗+甲泼尼龙120mg(溶于生理盐水,终体积100ml)每日一次共5天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The specific use of methylprednisolone in severe community-acquired pneumonia (SCAP) has not yet formed a consensus. It is not clear whether the clinical efficacy of methylprednisolone in SCAP is dose-dependent, and how to balance the best efficacy with the least complications. The aim of this study is to evaluate the efficacy and safety of different doses of methylprednisolone in the adjuvant treatment for patients with SCAP. METHODS/DESIGN: This is a prospective, randomized, double-blind, parallel group, placebo-controlled trial to evaluate the efficacy and safety of different doses of methylprednisolone in the adjuvant treatment for patients with SCAP. Patients with diagnosed SCAP are randomized to the following four groups at a 1:1:1:1 ratio: group 1 (control group)-standard ICU patient care+100ml of normal saline once a day for 5 days; group 2-standard ICU patient care+40mg of methylprednisolone (dissolved in normal saline with a final volume of 100ml) once a day for 5 days; group 3-standard ICU patient care+80mg of methylprednisolone (dissolved in normal saline with a final volume of 100ml) once a day for 5 days; and group 4-standard ICU patient care+120mg of methylprednisolone (dissolved in normal saline with a final volume of 100ml) once a day for 5 days. The primary outcome is PaO2/FiO2 ratio at day 5 following randomization. The secondary outcomes are 28-day mortality, ventilator-free days at 28 days, mechanical ventilation duration at 28 days, endotracheal intubation rate, time for temperature recovery, duration of vasopressors use, serum CRP and interleukin-6 level at day 5 following randomization, hospital stay, frequency of nosocomial infections, gastrointestinal hemorrhage, and hyperglycemia. DISCUSSION: The results of our study may find the optimal dose of glucocorticoid in the adjuvant treatment of SCAP and provide evidence-based proof for clinicians to treat patients with SCAP. Since coronavirus disease 2019 (COVID-19) also belongs to community-acquired pneumonia, perhaps the results of our study will help to determine the appropriate dose of methylprednisolone in COVID-19 treatment. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100045056 . Registered on 4 April 2021.
引用
- Hong S, Wang H, Liu J, et al. Effects of different doses of methylprednisolone on clinical outcomes in patients with severe community-acquired pneumonia: a study protocol for a randomized controlled trial. Trials. 2022. PMID: 35598005. doi:10.1186/s13063-022-06404-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。